Headquarters: Boston, Massachusetts, USA
Founded: 2012
Status: Public company (NASDAQ: AKLI)
Website: akiliinteractive.com
Akili Interactive is a leading digital therapeutics company that develops prescription video games and digital cognitive training programs to treat cognitive impairment across a range of neurological conditions. The company's flagship product, EndeavorRx, became the first FDA-cleared prescription video game for treating ADHD in children[1]. Founded in 2012 by Dr. Adam Gazzaley, a renowned neuroscientist from the University of California, San Francisco, Akili has pioneered the intersection of video game technology and evidence-based medicine to create a new category of therapeutic interventions[2].
Akili's platform is based on selective stimuli management (SSM), a novel approach that uses adaptive difficulty and sensory stimuli to target specific cognitive domains. This technology was developed based on years of neuroscience research demonstrating that carefully designed video game experiences can produce measurable improvements in cognitive function across multiple domains including attention, working memory, and executive function[3]. The company's mission extends beyond ADHD to address the significant unmet need for effective treatments for cognitive impairment in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease[4].
The origins of Akili Interactive trace back to research conducted at UCSF's Neuroscience and Imaging Lab, where Dr. Gazzaley and colleagues demonstrated that custom-designed video games could enhance cognitive abilities in older adults. These foundational studies showed that older adults who played specially designed games showed improvements in attention, working memory, and executive function that generalized beyond the training tasks[3:1]. This research provided the scientific foundation for what would become Akili's SSM technology platform.
The company was formally established in 2012 and initially focused on developing its core technology platform. In 2014, Akili received its first FDA clearance for a research tool, and subsequent years saw the company advance through multiple clinical trials culminating in the landmark 2020 approval of EndeavorRx as the first FDA-cleared prescription video game[5]. The company went public in 2021, trading on NASDAQ under the symbol AKLI, which provided capital for expanding its pipeline and commercial operations.
Akili's scientific advisory board includes leading researchers in cognitive neuroscience, neurology, and digital health, ensuring that the company's product development remains grounded in rigorous scientific evidence. The company has established partnerships with major academic medical centers to conduct clinical research and has published its results in peer-reviewed journals, including studies demonstrating the efficacy of its technology across various patient populations[6].
EndeavorRx represents a paradigm shift in the treatment of attention disorders. Originally known as AKL-T01 during clinical development, this prescription video game was specifically designed to treat attention deficit hyperactivity disorder in children ages 8-12 years old[5:1].
The mechanism of action involves presenting adaptive challenges that require sustained attention, cognitive flexibility, and impulse control. Unlike traditional pharmaceutical treatments that act through neurotransmitter modulation, EndeavorRx works by training specific neural circuits involved in attention through repeated, engaging gameplay experiences. The adaptive difficulty system ensures that each child receives an optimal level of challenge—neither too easy (which fails to engage the cognitive system) nor too difficult (which causes frustration and disengagement)[7].
Clinical trials demonstrated that EndeavorRx produced statistically significant improvements in ADHD symptoms as measured by the ADHD Rating Scale-5 (ADHD-RS-5) Attention Domain[8]. Notably, these improvements were observed without the side effects commonly associated with stimulant medications, including appetite suppression, sleep disruption, and mood changes. The game-based delivery also resulted in high patient adherence rates, addressing a significant challenge in traditional pharmacotherapy where compliance often declines over time[9].
Akili has developed cognitive training programs specifically for PD, recognizing that cognitive impairment is one of the most debilitating non-motor symptoms of the disease. Parkinson's disease affects millions of people worldwide, and up to 50% of patients develop mild cognitive impairment (PD-MCI) or dementia[10].
The company's PD-specific programs include:
Executive dysfunction is among the most common cognitive impairments in PD, affecting abilities such as planning, decision-making, working memory, and cognitive flexibility. These deficits are linked to frontostriatal circuit dysfunction resulting from dopaminergic neurodegeneration in the basal ganglia[11]. Akili's games are specifically designed to engage these frontostriatal circuits through tasks that require executive cognitive processes, potentially slowing or partially reversing cognitive decline in PD patients[12].
The motor-cognitive integration component is particularly innovative, as it addresses the unique challenge of combined motor and cognitive impairment in PD. Dual-task paradigms that require simultaneous motor and cognitive processing have shown promise in PD rehabilitation, and Akili's platform adapts this approach to an engaging digital format[13].
Akili's pipeline extends beyond its current approved products to address significant unmet needs across multiple neurological conditions:
Akili's products have been validated through multiple clinical trials across different indications, establishing a robust evidence base for the company's digital therapeutic approach[15].
The pivotal trial for EndeavorRx was a randomized, controlled study published in The Lancet Digital Health. This trial demonstrated that children with ADHD who used EndeavorRx showed significantly greater improvement in attention measures compared to a control group[8:1]. The improvement was measured using the ADHD Rating Scale-5 (ADHD-RS-5) Attention Domain, with statistically significant differences observed as early as week 4 of treatment.
Key findings from the clinical program include:
While Akili's PD programs are not yet FDA-cleared, the company has conducted early-phase clinical studies demonstrating proof of concept:
The scientific basis for Akili's approach rests on established neuroscience principles. Research has demonstrated that:
Akili's technology platform represents the integration of decades of cognitive neuroscience research with modern game development expertise.
The SSM platform is the core technology underlying Akili's products. This approach uses sophisticated algorithms to dynamically adjust game parameters based on real-time performance measurement[17]. Key features include:
Akili's games incorporate sensorimotor elements that require players to integrate sensory processing with motor responses. This approach is particularly relevant for PD, where sensorimotor integration is frequently impaired[18]. The games involve:
One of Akili's innovations is the development of digital biomarkers derived from gameplay performance. These objective measures have potential applications in:
Akili operates through a combination of prescription-based and direct-to-consumer models, reflecting the unique regulatory status of prescription digital therapeutics.
Like traditional pharmaceutical products, many of Akili's products require a prescription from a licensed healthcare provider. This model:
The reimbursement landscape for digital therapeutics is evolving rapidly. Key aspects of Akili's reimbursement strategy include:
Akili has established strategic partnerships with:
Akili's cognitive gaming platform is particularly relevant for PD because it addresses multiple aspects of the cognitive deficits that affect quality of life in PD patients.
Mild cognitive impairment in Parkinson's disease (PD-MCI) affects approximately 25-50% of patients and represents a significant predictor of progression to Parkinson's disease dementia. PD-MCI is characterized by deficits in:
Akili's platform targets these specific domains through game mechanics designed to engage the relevant neural circuits[19]. Unlike pharmacological approaches that may provide general cognitive stimulation, the targeted nature of the training allows for focused intervention on specific deficits.
Executive dysfunction in PD is directly linked to frontostriatal circuit dysfunction. The basal ganglia, which is severely affected by dopaminergic neurodegeneration in PD, plays a critical role in executive function through its connections with the prefrontal cortex[11:1]. Akili's games are designed to engage these circuits, potentially providing a form of circuit-specific rehabilitation.
The frontostriatal system is involved in:
A significant challenge in PD cognitive intervention is patient adherence. Traditional cognitive training can be tedious, leading to high dropout rates. Akili's game-based approach addresses this through:
Akili's digital therapeutics can be integrated into comprehensive Parkinson's disease management:
Akili operates in the emerging prescription digital therapeutics space, competing with both other digital therapeutics companies and traditional cognitive training approaches.
Akili faces competition from established cognitive training companies:
Akili's competitive advantage lies in its:
The regulatory pathway for prescription digital therapeutics represents a relatively new and evolving area of FDA oversight.
Akili's products are cleared through the FDA's 510(k) process, demonstrating that the device is substantially equivalent to a predicate device. This pathway requires:
The FDA has established several initiatives to support digital therapeutic development:
Akili's pipeline represents significant opportunities for expansion: